Study S002069

The Effect of Exenatide on Brown Adipose Tissue Activity and Energy Expenditure in Healthy Young Men

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT03002675
Acronym: exe01
Study type: INTERVENTIONAL
Phase: PHASE4
Masking: NONE
Status: UNKNOWN
Enrollment: 24
Start: 2016-08
Primary completion: 2018-06
Lead sponsor: Ingrid Jazet
Conditions: Obesity
Interventions: DRUG:Bydureon
Results posted: FALSE

Registered primary outcomes

The effect of exenatide on BAT activity and energy expenditure in healthy young South Asian compared to white Caucasian men [End of the study, up to 21 months]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0021522	Twelve weeks of exenatide treatment increases [18F]fluorodeoxyglucose uptake by brown adipose tissue without affecting oxidative resting energy expenditure in nondiabetic males. Janssen LGM, Metabolism: clinical and experimental	2020	Nonrandomized study	PMID 31982480 DOI	cites ClinicalTrials.gov:NCT03002675; registry reference DERIVED:31982480